Open AccessWork-up for Incidentally Detected NAFLD: How Far is It Worth?
Author(s) -
Harish Bhujade,
Saurabh Mishra,
Amna Subhan Butt,
Lubna Kamani,
Madhumita Premkumar
Publication year - 2022
Publication title -
euroasian journal of hepato-gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2231-5128
pISSN - 2231-5047
DOI - 10.5005/jp-journals-10018-1364
Subject(s) - medicine , metabolic syndrome , fatty liver , steatohepatitis , cirrhosis , transient elastography , steatosis , disease , hepatocellular carcinoma , gastroenterology , asymptomatic , diabetes mellitus , nonalcoholic fatty liver disease , fibrosis , liver disease , radiology , pathology , obesity , liver fibrosis , endocrinology
The incidence of nonalcoholic fatty liver disease (NAFLD) has seen a steep rise in parallel with the global obesity and metabolic syndrome epidemic. The presence of NAFLD contributes to significant socioeconomic burden due to healthcare costs, progression of liver disease as non-alcoholic steatohepatitis (NASH), and later cirrhosis and hepatocellular carcinoma (HCC). With the advent of widely available imaging, it is also being detected as an incidental diagnosis in individuals with systemic disease like metabolic syndrome, diabetes, chronic cardiac disease, polycystic ovarian syndrome, etc. or in asymptomatic persons on presurgical evaluation or even annual health assessments. Gastroenterologists, hepatologists, physicians and surgeons need to be updated about the new diagnostic criteria of Metabolic (dysfunction)-associated fatty liver disease, noninvasive tests (NITs) of liver fibrosis, new tools of elastography, and identification of those with high-risk disease. In this review, we appraise the relevance of new diagnostic definitions, steatosis and fibrosis estimation tests, advanced imaging like magnetic resonance elastography and proton density fat fraction and discuss the diagnostic algorithm for incidentally detected NAFLD.